Multiple Myeloma Hub
701 subscribers
6:12
What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
Multiple Myeloma Hub
28 views • 4 days ago
7:32
Symposium | Introduction to T-cell engagers and general mechanism of action
Multiple Myeloma Hub
77 views • 2 weeks ago
22:48
Symposium | BCMA-directed bispecific antibodies
Multiple Myeloma Hub
68 views • 2 weeks ago
16:43
Symposium | Practical management of adverse events with immunotherapies
Multiple Myeloma Hub
67 views • 2 weeks ago
9:04
Symposium | Looking to the future of bispecific antibodies in MM
Multiple Myeloma Hub
79 views • 2 weeks ago
9:08
Symposium | Q&A session
Multiple Myeloma Hub
27 views • 2 weeks ago
19:00
Symposium | Beyond BCMA: Novel strategies using bispecific antibodies
Multiple Myeloma Hub
44 views • 2 weeks ago
7:06
What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?
Multiple Myeloma Hub
54 views • 1 month ago
6:49
What are the management strategies for CRS and ICANS in MM?
Multiple Myeloma Hub
55 views • 1 month ago
8:50
What are the latest updates on trispecific antibodies for the treatment of MM?
Multiple Myeloma Hub
227 views • 2 months ago
9:36
What are the real-world outcomes following treatment with teclistamab in RRMM?
Multiple Myeloma Hub
131 views • 2 months ago
8:06
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Multiple Myeloma Hub
116 views • 2 months ago
3:37
Are CAR T-cell therapies effective in the treatment of extramedullary MM?
Multiple Myeloma Hub
156 views • 2 months ago
3:58
How does treatment with ide-cel impact quality of life in RRMM?
Multiple Myeloma Hub
74 views • 3 months ago
7:31
What is the impact of dexamethasone dose strength on outcomes in NDMM?
Multiple Myeloma Hub
208 views • 3 months ago
15:58
Patient case discussion on treating with CELMoDs
Multiple Myeloma Hub
164 views • 4 months ago
6:58
For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?
Multiple Myeloma Hub
125 views • 5 months ago
5:48
For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?
Multiple Myeloma Hub
55 views • 5 months ago
1:41
What is the rationale for combination venetoclax+Kd treatment in patients with t(11;14) RRMM?
Multiple Myeloma Hub
104 views • 5 months ago
3:26
How might IVIG therapy be used to treat infection after BCMA-targeted therapies in MM?
Multiple Myeloma Hub
141 views • 5 months ago
7:32
What are the pros and cons of bispecific antibodies and CAR T-cell therapies in myeloma?
Multiple Myeloma Hub
181 views • 5 months ago
5:33
What are the latest updates to the Portuguese MM treatment guidelines? [Portuguese]
Multiple Myeloma Hub
47 views • 6 months ago
6:14
What are the latest updates to the Portuguese MM treatment guidelines?
Multiple Myeloma Hub
82 views • 6 months ago
4:44
What factors influence the adoption rates of novel MM therapies in Latin America?
Multiple Myeloma Hub
79 views • 6 months ago
3:11
What factors influence the adoption rates of novel MM therapies in Latin America? [Portuguese]
Multiple Myeloma Hub
24 views • 6 months ago
3:58
What impact does osseous vs hematogenous extramedullary MM have on patient outcomes? [Spanish]
Multiple Myeloma Hub
37 views • 6 months ago
3:41
What impact does osseous vs hematogenous extramedullary MM have on patient outcomes?
Multiple Myeloma Hub
68 views • 6 months ago
5:28
How does linvoseltamab differ from other bispecific antibodies?
Multiple Myeloma Hub
215 views • 7 months ago
7:45
How can we better predict early relapse in multiple myeloma?
Multiple Myeloma Hub
302 views • 8 months ago
4:34
How to treat advanced refractory MM?
Multiple Myeloma Hub
109 views • 8 months ago
Load More